Podcast
Questions and Answers
What is the recommended therapy that includes ACEi, ARB, ARNI, and MRA?
What is the recommended therapy that includes ACEi, ARB, ARNI, and MRA?
- KDIGO
- ACC
- RAASi
- cRAASi (correct)
What type of inhibitor is angiotensin-converting enzyme?
What type of inhibitor is angiotensin-converting enzyme?
- Renin-angiotensin-aldosterone system inhibitor
- Angiotensin-converting enzyme inhibitor (correct)
- Mineralocorticoid receptor antagonist
- Angiotensin II receptor blocker
What is the level of evidence for the 2022 AHA/ACC/HFSA guideline?
What is the level of evidence for the 2022 AHA/ACC/HFSA guideline?
- Low-quality evidence from one or more RCTs and meta-analyses of low-quality RCTs
- High-quality evidence from one or more RCTs and meta-analyses of high-quality RCTs
- Moderate-quality evidence from one or more RCTs and meta-analyses of moderate-quality RCTs (correct)
- Very low-quality evidence from one or more RCTs and meta-analyses of very low-quality RCTs
When can ARBs be used?
When can ARBs be used?
What is the abbreviation for angiotensin receptor-neprilysin inhibitor?
What is the abbreviation for angiotensin receptor-neprilysin inhibitor?
What is the name of the receptor antagonist mentioned in the content?
What is the name of the receptor antagonist mentioned in the content?
What type of therapy is included in RAASi therapy?
What type of therapy is included in RAASi therapy?
What is the therapy used if a patient is intolerant to ACEi or ARNI?
What is the therapy used if a patient is intolerant to ACEi or ARNI?
What is the level of evidence for the recommendation in the 2022 AHA/ACC/HFSA guideline?
What is the level of evidence for the recommendation in the 2022 AHA/ACC/HFSA guideline?
What is the harm level of the recommendation in the 2022 AHA/ACC/HFSA guideline?
What is the harm level of the recommendation in the 2022 AHA/ACC/HFSA guideline?
What is the purpose of the KDIGO guidelines?
What is the purpose of the KDIGO guidelines?
What is the class of the recommendation in the 2022 AHA/ACC/HFSA guideline?
What is the class of the recommendation in the 2022 AHA/ACC/HFSA guideline?
What is the effect of RAASi therapy on renal K+ excretion?
What is the effect of RAASi therapy on renal K+ excretion?
Which of the following medications blocks angiotensin II formation?
Which of the following medications blocks angiotensin II formation?
What is the effect of angiotensin II on aldosterone release?
What is the effect of angiotensin II on aldosterone release?
Which of the following medications blocks aldosterone receptor binding?
Which of the following medications blocks aldosterone receptor binding?
What is the effect of RAASi therapy on urinary K+ excretion?
What is the effect of RAASi therapy on urinary K+ excretion?
Which of the following medications blocks angiotensin II-mediated aldosterone release?
Which of the following medications blocks angiotensin II-mediated aldosterone release?
What is the effect of aldosterone on potassium homeostasis?
What is the effect of aldosterone on potassium homeostasis?
Which of the following medications impairs renal K+ excretion?
Which of the following medications impairs renal K+ excretion?
What is the effect of hyperkalemia on RAASi therapy?
What is the effect of hyperkalemia on RAASi therapy?
Which of the following medications blocks the effect of angiotensin II on aldosterone release?
Which of the following medications blocks the effect of angiotensin II on aldosterone release?
Study Notes
RAASi Therapy and Heart Failure
- RAASi therapy includes ACEi, ARNI, and MRA.
- ARBs can be used if intolerant to ACEi or ARNI.
Guidelines and Recommendations
- 2022 AHA/ACC/HFSA guideline: Recommendation (3:Harm B-NR) suggests that RAASi therapy may harm patients with CKD.
- 2022 AHA/ACC/HFSA guideline: Recommendation (2b B-R) suggests that ARBs can be used if intolerant to ACEi or ARNI.
RAAS Inhibition and Hyperkalaemia
- RAAS inhibition impairs renal K+ excretion.
- Direct renin inhibitors and ACEi block angiotensin II formation, leading to impaired aldosterone release and hyperkalaemia.
- ARBs block angiotensin II-mediated aldosterone release, leading to hyperkalaemia.
- MRAs block aldosterone receptor binding, leading to hyperkalaemia.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
This quiz covers the guidelines and therapies for heart failure, including RAASi therapy, ARBs, and potassium-lowering agents, as recommended by the 2022 AHA/ACC/HFSA guideline.
